A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young ...

The study results revealed glycemic improvements using Omnipod 5 compared with insulin injections or pump therapy treatments in adults with type 2 diabetes. The outcome demonstrated significant ...

Insulet continues to see adoption of its Omnipod 5 pump—the device that represents Insulet's entrance into hybrid closed-loop technology that makes life easier by automating insulin delivery ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Omnipod 5 is recognized as the number one insulin pump for new pump users in Europe. Omnipod 5 is also the number one prescribed AID system in the United States and the first tubeless, waterproof ...

Curious as to what was inside, [Ido Roseman] tore down an Omnipod Dash and took some pictures ... communicate wirelessly with a control system, and pump insulin through the cannula as needed.

Insulet's Omnipod 5 device is the first such system to be ... to ease investor concerns about the potential hit on its insulin pump sales, given the soaring demand for the newer diabetes and ...

Perspective from Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 ...

Insulet's Omnipod The deal has been axed a few weeks after a federal judge in the US blocked EOFlow from selling its insulin patch pump in a lawsuit brought by Insulet, which sells a rival product.

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create an artificial pancreas system used by diabetics – and claimed that ...